
<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  
<!-- Mirrored from investors.scholarrock.com/node/7721/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:11:25 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <title>SEC Filing - Scholar Rock, Inc.</title>
    <meta name="robots" content="noindex">
    <link rel="stylesheet" media="all" href="../../sites/g/files/knoqqb56236/files/css/css_-Ogun-b4Vwq8nD6qwBoEYuBhEF_0grnAaUrH4akFvLUcd37.css?delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl" />

    
    <!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='../../../analytics.imirwin.com/js/container_XFyWYf0m.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WTGMF33');</script>
<!-- End Google Tag Manager -->

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="../../../www.googletagmanager.com/nsca0c.html?id=GTM-WTGMF33"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-sec-filing nir-node--7721 page-template-default page page-parent wp-custom-logo wp-embed-responsive full-width-content genesis-breadcrumbs-visible genesis-singular-image-hidden genesis-footer-widgets-visible top-parent-investors-media investors-media has-no-blocks elementor-default elementor-page cbp-spmenu-push cookies-set cookies-accepted body_classes" id="body" cz-shortcut-listen="true">
      <div class="region region-content">
    <div id="block-nir-pid2662-websitenoticeblock" class="block--website-notice-block block--website-notice-block--7721 block--content--website-notice-block block--content--website-notice-block--7721 block--24a64b1d-13aa-4b20-8029-2df59f99a96c block--24a64b1d-13aa-4b20-8029-2df59f99a96c--7721 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2662-content" class="block--system-main-block block--system-main-block--7721 block--content--system-main-block block--content--system-main-block--7721 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0--7721 block block-system block-system-main-block">
  
    
      <div class="nir-sec-header"><div class="logo"><img src="../../sites/g/files/knoqqb56236/files/Logo.png" alt="Scholar Rock, Inc." />
</div><div class="sec-docs">View:  <div class="field ixbrl-link">
    <a href="ixbrl-viewer"></a>
  </div>
  <div class="file-link">
  <span class="file file--mime-application-rtf file--general"> <a href="../../static-files/0001157523-20-001347.rtf%3b%20filename_%3dUTF-8%27%270001157523-20-001347.rtf" type="application/rtf" title="0001157523-20-001347.rtf">Download DOC</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="../../static-files/0001157523-20-001347.pdf%3b%20filename_%3dUTF-8%27%270001157523-20-001347.pdf" type="application/pdf" title="0001157523-20-001347.pdf">Download PDF</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-vnd-ms-excel file--x-office-spreadsheet"> <a href="../../static-files/0001157523-20-001347.xls%3b%20filename_%3dUTF-8%27%270001157523-20-001347.xls" type="application/vnd.ms-excel" title="0001157523-20-001347.xls">Download XLS</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-octet-stream file--general"> <a href="../../sec-filings/sec-filing/8-k/0001157523-20-001347.html" type="application/octet-stream" title="0001157523-20-001347-ex-101-sch---xbrl-taxonomy-extension-schema.xsd">Download XBRL</a></span><span class="filesize"> </span>
</div>
</div></div>
    <XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srrk="http://scholarrock.com/20201027" xmlns="../../../www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: business wire
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2020 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_6a38e8e0679c4f878545f82646c44ef5" contextRef="c20201027to20201027" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_dbbf6f1e8bca40aa9a67fd01ad6cbb09" contextRef="c20201027to20201027">0001727196</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="#srrk-20201027.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20201027to20201027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-27</xbrli:startDate><xbrli:endDate>2020-10-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div>
      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">UNITED


          STATES</span><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          SECURITIES AND EXCHANGE COMMISSION</span><br />
        <span style="font-weight: bold;">Washington, D.C. 20549</span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">FORM


          <ix:nonNumeric name="dei:DocumentType" id="Fact_09f893ac65b64bd2af919812d86dc10f" contextRef="c20201027to20201027">8-K</ix:nonNumeric></span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">CURRENT REPORT</div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      <div>&#160;</div>

      <div style="text-align: center;">Date of Report (Date of earliest event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_64826db5d9994bcdb0f91e3d42e185ff" contextRef="c20201027to20201027" format="ixt:datemonthdayyearen">October 27, 2020</ix:nonNumeric></div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_cdf22c7e9e9e4a5b98583a7a4a92178a" contextRef="c20201027to20201027">Scholar Rock Holding Corp</ix:nonNumeric>oration</span><br />
        (Exact Name of Registrant as Specified in Charter)</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" id="z107cf8ce03914b7f865c0dfc5f27fdba" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_133f6767a4334c3493656a9acf99f21b" contextRef="c20201027to20201027" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_95b56c66f72448a9a4b024dcb0f7375c" contextRef="c20201027to20201027">001-38501</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_530618c7a58c41f2bc8c7db5a7706a40" contextRef="c20201027to20201027">82-3750435</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(I.R.S. Employer Identification Number)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: center;"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_e2fdab5df4d24497997d3099e547e554" contextRef="c20201027to20201027">620 Memorial Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_54ada3a24048475fa8ee86a653089dfd" contextRef="c20201027to20201027">2nd Floor</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_80d4ab5dc642408ea1c3d363d544bb33" contextRef="c20201027to20201027">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_065e36a834994ad893301f7d28fa6d04" contextRef="c20201027to20201027">MA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_2c3e06425b5245b5936bada4cb19b8b9" contextRef="c20201027to20201027">02139</ix:nonNumeric></span><br />
        (Address of Principal Executive Offices) (Zip Code)</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_ea4a5ac3f0354070b74903b2fb1e00d6" contextRef="c20201027to20201027">857</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_1c6cd6dfe0484ac489a528cb833ecc83" contextRef="c20201027to20201027">259-3860</ix:nonNumeric></span><br />
        (Registrant&#8217;s telephone number, including area code)</div>

      <div>&#160;</div>

      <div style="text-align: center;">(Former name or former address, if changed since last report)</div>

      <div>&#160;</div>

      <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

      <div>&#160;</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_52f6e2889ea94cedb0a8159a3a627079" contextRef="c20201027to20201027" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Written



        communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_62a24276469d467c9a2d7695d3efe004" contextRef="c20201027to20201027" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Soliciting



        material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_6526f82ce8d348818105809a884b346b" contextRef="c20201027to20201027" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement



        communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_eb644e9521f7462c80a2bcdcb8ba837a" contextRef="c20201027to20201027" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement



        communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

      <div>&#160;</div>

      <div>Securities registered pursuant to Section 12(b) of the Act:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" id="z70d7d1ffb9404515954838ce95d0dafe" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Trading Symbol(s)</div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_6746e1df272d45149f13609973c0f4a7" contextRef="c20201027to20201027">Common Stock, par value $0.001 per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_79668de9e0554c8faef76ac262f469ea" contextRef="c20201027to20201027">SRRK</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_daa64774cac54424ba60cc92a568b361" contextRef="c20201027to20201027" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div>&#160;</div>

      <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging growth company
        <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_150aeedcaf754a0892d450adefbeecdf" contextRef="c20201027to20201027" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div>&#160;</div>

      <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
        Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" id="Fact_ff8bee4323f64a47861c7acc5c276969" contextRef="c20201027to20201027" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div>&#160;</div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div style="font-weight: bold;"> <br />
      </div>

      <div style="font-weight: normal;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z019c613d320b4cdf8cc8896fd5ad10a7">


  <tr>

    <td style="width: 10%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.01.</div>
              </td>

    <td style="width: 90%; vertical-align: middle;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Regulation FD Disclosure.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">On October 27, 2020, <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Scholar Rock Holding Corporation</span> (the &#8220;Company&#8221;)
          issued a press release announcing positive six-month interim analysis results from the SRK-015 TOPAZ Phase 2 clinical trial. A copy of the press release is attached hereto as Exhibit 99.1.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The information in this Item 7.01 of Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the
          Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act,
          regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.</div>

        <div>&#160;</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zd43714f3f322414385b8dba80c9b6799">


  <tr>

    <td style="width: 10%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 8.01.</div>
              </td>

    <td style="width: 90%; vertical-align: middle;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Other Events.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">On October 27, 2020, the Company will host a conference call and webcast <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">at
            8:00 am ET on Tuesday, October 27, 2020 </span>to discuss the interim analysis from the SRK&#8209;015 TOPAZ Phase 2 clinical trial. A copy of the presentation slides used by the Company during the conference call and webcast is attached hereto as
          Exhibit 99.2 and is incorporated herein by reference. <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">A live webcast of the conference call may be accessed by visiting the Investors &amp; Media section of the Company&#8217;s
            website at http://investors.scholarrock.com.</span></div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="za8379c4cbfb84677915175a3c01d1f42">


  <tr>

    <td style="width: 10%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01.</div>
              </td>

    <td style="width: 90%; vertical-align: middle;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits:</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z20554138298242aca36a7d3691abb52a">


  <tr>

    <td style="width: 0.1%; vertical-align: middle;">&#160;</td>

    <td style="width: 5.32%; vertical-align: middle;">&#160;</td>

    <td style="width: 0.49%; vertical-align: middle;">&#160;</td>

    <td style="width: 4.85%; vertical-align: middle;">&#160;</td>

    <td style="width: 89.24%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td colspan="2" style="width: 5.42%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br />
                  </span>No.</div>
              </td>

    <td style="width: 0.49%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 4.85%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89.24%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
              </td>

  </tr>

  <tr>

    <td style="width: 0.1%; vertical-align: middle;">&#160;</td>

    <td style="width: 5.32%; vertical-align: middle;">&#160;</td>

    <td style="width: 0.49%; vertical-align: middle;">&#160;</td>

    <td style="width: 4.85%; vertical-align: middle;">&#160;</td>

    <td style="width: 89.24%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 0.1%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 5.32%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a52314353ex99_1.htm">99.1</a></div>
              </td>

    <td style="width: 0.49%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 4.85%; vertical-align: top;">&#160;</td>

    <td style="width: 89.24%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a52314353ex99_1.htm">Press Release issued
                    by Scholar Rock Holding Corporation, dated October 27, 2020</a></div>
              </td>

  </tr>

  <tr>

    <td style="width: 0.1%; vertical-align: middle;">&#160;</td>

    <td style="width: 5.32%; vertical-align: middle;">&#160;</td>

    <td style="width: 0.49%; vertical-align: middle;">&#160;</td>

    <td style="width: 4.85%; vertical-align: middle;">&#160;</td>

    <td style="width: 89.24%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 0.1%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 5.32%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a52314353ex99_2.htm">99.2</a></div>
              </td>

    <td style="width: 0.49%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 4.85%; vertical-align: top;">&#160;</td>

    <td style="width: 89.24%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a52314353ex99_2.htm">Presentation Slide
                    Deck</a></div>
              </td>

  </tr>

  <tr>

    <td style="width: 0.1%; vertical-align: middle;">&#160;</td>

    <td style="width: 5.32%; vertical-align: middle;">&#160;</td>

    <td style="width: 0.49%; vertical-align: middle;">&#160;</td>

    <td style="width: 4.85%; vertical-align: middle;">&#160;</td>

    <td style="width: 89.24%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 0.1%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 5.32%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
              </td>

    <td style="width: 0.49%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 4.85%; vertical-align: top;">&#160;</td>

    <td style="width: 89.24%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        </div>

        <div>&#160;</div>

        <div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

        </div>

        <div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the&#160;Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
            undersigned hereunto duly authorized.</div>

          <div><br />
          </div>

          <div><br />
          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf82f04729abd46f9b77cb1fc42868819">


  <tr>

    <td style="width: 50.06%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="2" style="width: 49.94%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Scholar Rock Holding Corporation</div>
              </td>

  </tr>

  <tr>

    <td style="width: 50.06%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 3.1%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 46.84%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 50.06%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: October 27, 2020</div>
              </td>

    <td style="width: 3.1%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
              </td>

    <td style="width: 46.84%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">/s/ Junlin Ho</span></div>
              </td>

  </tr>

  <tr>

    <td style="width: 50.06%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 3.1%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 46.84%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Junlin Ho</div>
              </td>

  </tr>

  <tr>

    <td style="width: 50.06%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 3.1%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 46.84%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Senior Vice President, Head of Legal</div>
              </td>

  </tr>


</table>
      </div>

      <br />
    </div>

  </div>

</body>

<!-- Mirrored from investors.scholarrock.com/node/7721/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:11:25 GMT -->
</html>
</XBRL>
<div><a name="a52314353ex99_1.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <table cellspacing="0" cellpadding="0" border="0" id="z0c42741c74234539a015a0c4e1c7359e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

        <tr>
          <td style="width: 50.00%;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.00%;">
            <div style="text-align: right;"><font style="font-weight: bold;">&#160;Exhibit 99.1</font><br>
            </div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div> <br>
    </div>
    <div>
      <div class="bw-release">
        <div class="bw-release">
          <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular
              Atrophy</b> </h1>
          <div class="bw-release-subhead">
            <p style="text-align: center; list-style-position: inside;"><b> - <i>Motor function improvements were observed for all three SRK-015 treatment cohorts in the primary efficacy endpoints (Hammersmith scale scores) at six-months; top-line data
                  from the 12-month treatment period are anticipated in 2Q21</i> </b></p>
            <p style="text-align: center; list-style-position: inside;"><b> - <i>SRK-015 dose response in the primary efficacy endpoint was observed in the randomized, double-blind cohort, with high dose attaining a 5.6 point mean improvement at
                  six-months over baseline compared to low dose attaining a 2.4 point mean improvement over baseline</i> </b></p>
            <p style="text-align: center; list-style-position: inside;"><b> - <i>First clinical data showing the potential therapeutic benefits of Scholar Rock&#8217;s innovative scientific platform of inhibiting the activation of latent myostatin</i> </b></p>
            <p style="text-align: center; list-style-position: inside;"><b> - <i>First demonstration of the therapeutic potential of the Company&#8217;s proprietary approach of targeting the latent forms of growth factors</i> </b></p>
            <p style="text-align: center; list-style-position: inside;"><b> - <i>Scholar Rock to host webcast today at 8:00am ET</i> </b></p>
          </div>
          <div class="bw-release-body">
            <div class="bw-release-table-js bw-release-story">
              <p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--October 27, 2020--Scholar Rock(NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today
                announced positive six-month interim analysis results from the TOPAZ Phase 2 clinical trial. Treatment with SRK-015 led to improvements in Hammersmith scale scores (primary efficacy endpoint) in all three cohorts of patients with Type 2 and
                Type 3 Spinal Muscular Atrophy (SMA). Dose response in the primary efficacy endpoint was observed across all evaluated timepoints in the double-blind, randomized portion of the trial (Cohort 3). The high-dose arm of Cohort 3 attained a 5.6
                point mean improvement from baseline in the Hammersmith Functional Motor Scale Expanded (HFMSE) as compared to the low dose arm, which attained a 2.4 point mean improvement at the six-month interim analysis timepoint. No safety signals were
                identified from the interim analysis. </p>
              <p> &#8220;These interim results are important because they demonstrate the potential of this muscle-directed approach to improve motor function of individuals with Type 2 and Type 3 SMA,&#8221; said Thomas Crawford, M.D., Professor of Neurology at the
                Johns Hopkins University School of Medicine and Lead Investigator of the TOPAZ trial. &#8220;In the last few years, we&#8217;ve celebrated the remarkable success in treating SMA with SMN-upregulating approaches that stabilize against neurodegeneration.
                These findings highlight the potential for a whole new approach to SMA therapy, used in conjunction with the SMN-enhancing therapies, to address the persistent and significant unmet needs of individuals weakened by SMA.&#8221; </p>
              <p> &#8220;This is an exciting and important step towards establishing SRK-015 as the potential first muscle-directed therapy for patients with SMA, while also providing important validation of our scientific approach of targeting the latent forms
                of growth factors,&#8221; said Yung Chyung, M.D., Chief Medical Officer of Scholar Rock. &#8220;These interim data support the continuation of the TOPAZ trial and we look forward to engaging with regulatory authorities regarding our registrational
                trial plans.&#8221; </p>
              <div> </div>
              <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
                <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                  <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
              </div>
              <p> <b>TOPAZ Phase 2 Six-Month Interim Results</b> </p>
              <p> SRK-015 is a highly selective inhibitor of the activation of latent myostatin. The TOPAZ Phase 2 proof-of-concept trial enrolled 58 patients with Type 2 and Type 3 SMA across 16 study sites in the U.S. and Europe. The trial is evaluating
                the safety and efficacy of intravenous SRK-015 dosed every four weeks (Q4W) over a 12-month treatment period. A pre-planned interim analysis was conducted following a six-month treatment period across all three study cohorts. Three patients
                (one in Cohort 2 and two in Cohort 3) each missed three doses of SRK-015 and the six-month interim analysis timepoint due to COVID-19-related site access restrictions; the six-month timepoint from these patients was not included in the
                interim analysis. </p>
              <p> At the six-month interim analysis timepoint: </p>
              <ul style="list-style-type: disc;">
                <li> Mean increases from baseline in Hammersmith scale scores were observed in all three cohorts. </li>
              </ul>
              <p style="margin-left: 30px;"> - 67% of total patients achieved &#8805;1 point improvement in Hammersmith scores. </p>
              <ul style="list-style-type: disc;">
                <li> Substantial proportion of patients in each cohort achieved a &#8805;3 point increase in Hammersmith scores. </li>
              </ul>
              <p style="margin-left: 30px;"> - 35% of total patients achieved &#8805;3 point increase in Hammersmith scores. </p>
              <p> Dose response in the primary efficacy endpoint was observed in the randomized, double-blind cohort; numerically greater improvements in HFMSE scores were observed for high-dose (20 mg/kg) arm across all evaluated timepoints. </p>
              <p> <strong><i><u>Detailed Summary of Interim Results by Cohort</u></i></strong> </p>
              <p> <strong>Cohort 1:</strong> This open-label, single-arm cohort enrolled 23 patients with ambulatory Type 3 SMA. Patients are being treated with 20 mg/kg of SRK-015 Q4W either as a monotherapy or in conjunction with an approved SMN
                upregulator therapy (nusinersen). The primary objectives of the cohort are to assess safety and the mean change from baseline in Revised Hammersmith Scale (RHS). </p>
              <p> At baseline, patients across both subgroups of patients had a mean age of 12.6 years (range 7-21 years) and a RHS score of 49.6 (range 26-63) out of a total possible score of 69. Patients in the SRK-015 monotherapy group had a mean age of
                12.1 years (range 7-19 years) and a mean RHS score of 47.6 (range 26-63). Patients in the group treated with SRK-015 and receiving an SMN upregulator (nusinersen) had a mean age of 13.1 years (range 7-21 years) and a mean RHS score of 51.3
                (range 43-62). One patient discontinued from the trial for reasons that were assessed to be unrelated to SRK-015 but was included in the intent-to-treat interim analysis. </p>
              <p> At the six-month interim analysis timepoint: </p>
              <ul style="list-style-type: disc;">
                <li> Mean change from baseline in RHS score: </li>
              </ul>
              <p style="margin-left: 30px;"> - SRK-015 pooled (n = 23): +0.5 points (95% CI of -1.1, +2.2) </p>
              <p style="margin-left: 30px;"> - SRK-015 monotherapy (n = 11): +0.7 points (95% CI of -2.5, +4.0) </p>
              <p style="margin-left: 30px;"> - SRK-015 + nusinersen (n = 12): +0.3 points (95% CI of -1.4, +2.0) </p>
              <ul style="list-style-type: disc;">
                <li> Proportion of patients attaining &#8805;1 point increase in RHS score: </li>
              </ul>
              <p style="margin-left: 30px;"> - SRK-015 pooled: 52% (12/23) </p>
              <p style="margin-left: 30px;"> - SRK-015 monotherapy: 64% (7/11) </p>
              <p style="margin-left: 30px;"> - SRK-015 + nusinersen: 42% (5/12) </p>
              <ul style="list-style-type: disc;">
                <li> Proportion of patients attaining &#8805;3 point increase in RHS score: </li>
              </ul>
              <p style="margin-left: 30px;"> - SRK-015 pooled: 26% (6/23) </p>
              <p style="margin-left: 30px;"> - SRK-015 monotherapy: 36% (4/11) </p>
              <p style="margin-left: 30px;"> - SRK-015 + nusinersen: 17% (2/12) </p>
              <ul style="list-style-type: disc;">
                <li> Proportion of patients attaining &#8805;5 point increase in RHS score: </li>
              </ul>
              <p style="margin-left: 30px;"> - SRK-015 pooled: 9% (2/23) </p>
              <p style="margin-left: 30px;"> - SRK-015 monotherapy: 9% (1/11) </p>
              <p style="margin-left: 30px;"> - SRK-015 + nusinersen: 8% (1/12) </p>
              <div> </div>
              <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
                <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                  <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
              </div>
              <p> <strong>Cohort 2:</strong> This open-label, single-arm cohort enrolled 15 patients with a mean age of 11.7 years (range 8-19 years) with Type 2 or non-ambulatory Type 3 SMA and who are already receiving treatment with an approved SMN
                upregulator. Patients are being treated with 20 mg/kg of SRK-015 Q4W in conjunction with an approved SMN upregulator therapy (nusinersen). At baseline, patients had a mean HFMSE score of 22.7 (range 13-39) out of a total possible score of
                66. One patient missed three doses of SRK-015 and the six-month interim analysis timepoint due to COVID-19-related site access restrictions; the six-month timepoint from this patient was not included in the interim analysis. The primary
                objectives of the cohort are to assess safety and the mean change from baseline in HFMSE. </p>
              <p> At the six-month interim analysis timepoint: </p>
              <ul style="list-style-type: disc;">
                <li> Mean change from baseline in HFMSE score (n = 14): +1.4 points (95% CI of +0.1, +2.7) </li>
              </ul>
              <ul style="list-style-type: disc;">
                <li> Proportion of patients attaining &#8805;1 point increase in HFMSE score: 71% (10/14) </li>
              </ul>
              <ul style="list-style-type: disc;">
                <li> Proportion of patients attaining &#8805;3 point increase in HFMSE score: 21% (3/14) </li>
              </ul>
              <ul style="list-style-type: disc;">
                <li> Proportion of patients attaining &#8805;5 point increase in HFMSE score: 14% (2/14) </li>
              </ul>
              <ul style="list-style-type: disc;">
                <li> Improvements in HFMSE scores progressively increased over the six-month treatment period, and a plateau in improvement appears to not have yet been reached. Twelve-month data may provide additional insights evaluating the potential for
                  durability of effect and for further motor function gains. </li>
              </ul>
              <p> <strong>Cohort 3:</strong> This randomized<b>,</b> double-blind, portion of the trial enrolled patients with Type 2 SMA who had initiated treatment with an approved SMN upregulator (nusinersen) before five years of age. Twenty patients
                were randomized in a 1:1 ratio to receive the low dose (2 mg /kg SRK-015 Q4W) or high dose (20 mg/kg SRK-015 Q4W); both treatment arms are in conjunction with an approved SMN upregulator therapy (nusinersen). Two patients (one in high-dose
                arm and one in low-dose arm) each missed three doses of SRK-015 and the six-month interim analysis timepoint due to COVID-19-related site access restrictions; the six-month timepoint from these patients was not included in the interim
                analysis. The primary objectives of the cohort are to assess safety and the mean change from baseline in HFMSE. </p>
              <p> At baseline, patients in the high-dose arm had a mean age of 3.8 years (range 2-6 years) and mean HFMSE score of 23.5 (range 14-42) out of a total possible score of 66 points, while patients in the low dose arm had a mean age of 4.1 years
                (range 2-6 years) and a mean HFMSE score of 26.1 (range 12-44). </p>
              <div> </div>
              <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
                <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                  <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
              </div>
              <p> At the six-month interim analysis timepoint: </p>
              <ul style="list-style-type: disc;">
                <li> Mean change from baseline in HFMSE score: </li>
              </ul>
              <p style="margin-left: 30px;"> - 20 mg/kg dose (n = 9): +5.6 points (95% CI of +2.5, +8.7) </p>
              <p style="margin-left: 30px;"> - 2 mg/kg dose (n = 9): +2.4 points (95% CI of -0.9, +5.8) </p>
              <ul style="list-style-type: disc;">
                <li> Proportion of patients attaining &#8805;1 point increase in HFMSE score: </li>
              </ul>
              <p style="margin-left: 30px;"> - 20 mg/kg dose: 100% (9/9) </p>
              <p style="margin-left: 30px;"> - 2 mg/kg dose: 67% (6/9) </p>
              <ul style="list-style-type: disc;">
                <li> Proportion of patients attaining &#8805;3 point increase in HFMSE score: </li>
              </ul>
              <p style="margin-left: 30px;"> - 20 mg/kg dose: 67% (6/9) </p>
              <p style="margin-left: 30px;"> - 2 mg/kg dose: 44% (4/9) </p>
              <ul style="list-style-type: disc;">
                <li> Proportion of patients attaining &#8805;5 point increase in RHS score: </li>
              </ul>
              <p style="margin-left: 30px;"> - 20 mg/kg dose: 56% (5/9) </p>
              <p style="margin-left: 30px;"> - 2 mg/kg dose: 33% (3/9) </p>
              <p> <i>Greater improvement achieved with high dose</i>: Patients treated with high dose (20 mg/kg) achieved numerically greater improvements from baseline in HFMSE scores as compared to the low dose (2 mg/kg) at all assessed timepoints (week
                8, week 16, and the six-month interim analysis timepoint). </p>
              <ul style="list-style-type: disc;">
                <li> Numerically greater improvements with high dose were observed both in terms of mean change from baseline and in proportions of patients attaining &#8805;3 point increase in HFMSE score. </li>
              </ul>
              <p> <i>Plateau in improvement appears to not have yet been reached</i>: Improvements in HFMSE scores progressively increased over the six-month treatment period. Twelve-month data may provide additional insights evaluating the potential for
                durability of effect and for further motor function gains. </p>
              <p> <i>PK and PD results are supportive of the observed dose response in efficacy:</i> </p>
              <ul style="list-style-type: disc;">
                <li> Treatment with the high dose led to higher levels of drug exposure than with the low dose. </li>
              </ul>
              <ul style="list-style-type: disc;">
                <li> Treatment with high dose achieved higher levels of target engagement, and treatment with low dose did not attain full target saturation. </li>
              </ul>
              <p> <b>Overall Safety and Tolerability: </b>No safety signals were identified during the interim analysis. </p>
              <ul style="list-style-type: disc;">
                <li> Incidence and severity of adverse events were consistent with underlying patient population and background therapy. </li>
              </ul>
              <ul style="list-style-type: disc;">
                <li> Five most frequently reported TEAEs: Headache, upper respiratory tract infection, pyrexia, nasopharyngitis, and cough. </li>
              </ul>
              <ul style="list-style-type: disc;">
                <li> No grade 3 (severe) or higher adverse events were reported. </li>
              </ul>
              <ul style="list-style-type: disc;">
                <li> One patient (Cohort 1) experienced a serious treatment-emergent adverse event (TEAE) of Grade 2 viral upper respiratory tract infection leading to hospitalization. The event was resolved without sequelae and was assessed by the trial
                  investigator as unrelated to study drug. </li>
              </ul>
              <ul style="list-style-type: disc;">
                <li> One patient (Cohort 1) discontinued from the trial due to Grade 2 muscle fatigue that started prior to initiation of dosing with study drug; assessed by the trial investigator as unrelated to study drug. </li>
              </ul>
              <p> Top-line data from the 12-month treatment are expected in the second quarter of 2021. Twelve-month data may provide additional insights evaluating the potential for durability of effect and for further motor function gains. </p>
              <div> </div>
              <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
                <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                  <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
              </div>
              <p> As of October 23, 2020, 39 of 39 patients who have completed the 12-month treatment period have opted into the extension period. </p>
              <p> <b>Conference Call/Webcast: <br>
                </b>Scholar Rock will host a conference call and audio webcast to discuss the SRK-015 TOPAZ Phase 2 clinical trial interim data today at 8:00 a.m. Eastern Time. To participate in the call, please dial 833-519-1308 (domestic) or 914-800-3874
                (international) and refer to conference ID: 1856917. A webcast of the call will also be available on the Investors &amp; Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will
                be available on Scholar Rock&#8217;s website at: https://scholarrock.com/ for approximately 90 days following the presentation. </p>
              <p> <b>About SMA <br>
                </b>Spinal muscular atrophy (SMA) is a rare, and often fatal, genetic disorder that typically manifests in young children. An estimated 30,000 to 35,000 patients are afflicted with SMA in the United States<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup> and Europe<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup>.
                It is characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk and progressive muscle weakness. The underlying pathology of SMA is caused by insufficient production of the SMN (survival of motor
                neuron) protein, essential for the survival of motor neurons, and is encoded by two genes, SMN1 and SMN2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup>. While there has been progress in the development of therapeutics that address the underlying SMA genetic defect, there
                continues to be a high unmet need for therapeutics that directly address muscle atrophy. </p>
              <p> (1) Lally, C. et al. Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. <i>Orphanet Journal of Rare Diseases</i>. (2017) 12:175. <br>
                (2) Briefing Document to the Clinical Trial Readiness in Spinal Muscular Atrophy (SMA) SMA Europe, TREAT-NMD and European Medicines Agency meeting. Prepared by SMA Europe and TREAT-NMD. November 11, 2016. <br>
                (3) Parente, V. and Corti, S. Advances in spinal muscular atrophy therapeutics. <i>Therapeutic Advances in Neurological Disorders. </i>(2018) 11:1. </p>
              <p> <b>About SRK-015 <br>
                </b>SRK-015 is a selective inhibitor of the activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA). Myostatin, a member of the TGF&#946; superfamily of growth factors,
                is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species. Scholar Rock believes the inhibition of the activation of myostatin with
                SRK-015 may promote a clinically meaningful increase in muscle strength. A Phase 2 clinical trial in patients with Type 2 and Type 3 SMA is ongoing. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) and
                Rare Pediatric Disease (RPD) designation, and the European Commission (EC) has granted Orphan Medicinal Product Designation, to SRK-015 for the treatment of SMA. The effectiveness and safety of SRK-015 have not been established and SRK-015
                has not been approved for any use by the FDA or any other regulatory agency. </p>
              <div> </div>
              <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
                <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                  <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
              </div>
              <p> <b>About Scholar Rock <br>
                </b>Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
                Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar
                Rock&#8217;s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platformfor the discovery and development of monoclonal antibodies that locally and selectively target these signaling
                proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock
                believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn
                (https://www.linkedin.com/company/scholar-rock/). </p>
              <p> Scholar Rock&#174; is a registered trademark of Scholar Rock, Inc. </p>
              <p> <b>Forward-Looking Statements <br>
                </b>This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the potential of SRK-015, Scholar Rock&#8217;s future
                expectations, plans and prospects, including without limitation, Scholar Rock&#8217;s expectations regarding its growth, strategy, progress and timing of its clinical trials for SRK-015, , the potential of its proprietary platform, and its
                intellectual property protection.<i> </i>The use of words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar
                expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could
                cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the possibility that data from the TOPAZ final analysis will be
                inconsistent with the data observed in the interim analysis, Scholar Rock&#8217;s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated
                from Scholar Rock&#8217;s nonclinical and preclinical studies and clinical trials, competition from third parties that are developing products for similar uses, Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property,
                Scholar Rock&#8217;s dependence on third parties for development and manufacture of product candidates including to supply any clinical trials, Scholar Rock&#8217;s ability to manage expenses and to obtain additional funding when needed to support its
                business activities and establish and maintain strategic business alliances and new business initiatives, and the impacts of public health pandemics such as COVID-19 on business operations including its TOPAZ clinical trial, as well as
                those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, as well as discussions of potential risks, uncertainties, and other important
                factors in Scholar Rock&#8217;s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock&#8217;s views only as of today and should not be relied upon as representing its views as of any
                subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law. </p>
            </div>
            <div class="bw-release-contact">
              <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
              <p> <b>Scholar Rock Contact: </b><br>
                Investors/Media <br>
                Catherine Hu <br>
                chu@scholarrock.com<br>
                917-601-1649 </p>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
<div><a name="a52314353ex99_2.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zf04cf6e2fed541a0a009d9bfc1a2fad3">

        <tr>
          <td style="width: 50.00%;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.00%;">
            <div style="text-align: right;"><font style="font-weight: bold;">&#160;Exhibit 99.2</font><br>
            </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <title></title>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide1.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;TOPAZ Interim Analysis: SRK-015 Demonstrates Clinical Proof-of-Concept in Spinal Muscular
              Atrophy&#160;&#160;October 27, 2020&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide2.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Disclaimers&#160;&#160;Various statements in this presentation concerning the future expectations, plans and
              prospects of Scholar Rock, Inc. (&#8220;Scholar Rock&#8221;), including without limitation, Scholar Rock&#8217;s expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting
              results from its clinical trials for its product candidates, its disease indication selection and timing for such selection, the ability of SRK-015 to affect the treatment of patients suffering from Spinal Muscular Atrophy (SMA) either as a
              monotherapy or in conjunction with the current standard of care, and the ability of SRK-181 to affect the treatment of cancer patients in a manner consistent with preclinical data constitute forward-looking statements for the purposes of the
              safe harbor provisions under The Private Securities Litigation Reform Act of 1995. The use of words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221;
              &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions are intended to identify such forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important
              factors, including, without limitation, Scholar Rock&#8217;s ability to provide the financial support and resources necessary to identify and develop multiple product candidates on the expected timeline, competition from others developing products
              for similar uses, the preliminary nature of interim clinical data, Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property, Scholar Rock&#8217;s dependence on third parties for development and manufacture of product
              candidates including to supply any clinical trials, and Scholar Rock&#8217;s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new
              business initiatives as well as those risks more fully discussed in the section entitled "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended&#160;June 30, 2020, which is on file with the&#160;Securities and Exchange Commission, as
              well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock&#8217;s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock&#8217;s views only as of
              today and should not be relied upon as representing its views as of any subsequent date. Scholar Rock explicitly disclaims any obligation to update any forward-looking statements unless required by law. &#160;&#160;&#169; Scholar Rock, Inc. All rights
              reserved. October 2020. &#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide3.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Agenda&#160;&#160;3&#160;&#160;Opening Remarks &#160;&#160;Trial Design and Baseline Characteristics&#160;&#160;6-month Interim Efficacy and
              Safety Results&#160;&#160;Summary and Next Steps&#160;&#160;Tony Kingsley, President &amp; CEO&#160;&#160;Yung Chyung M.D., Chief Medical Officer&#160;&#160;Yung Chyung M.D., Chief Medical Officer&#160;&#160;Tony Kingsley, President &amp; CEO&#160;&#160;&#160;&#160;Questions and Answers&#160;&#160;Tony Kingsley,
              President &amp; CEOYung Chyung M.D., Chief Medical OfficerTed Myles, Chief Financial Officer&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide4.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SRK-015 Has Potential to Pioneer a New Treatment Era to Improve Motor Function in Patients with
              SMA&#160;&#160;4&#160;&#160;SMN = survival motor neuron. *Also referred to as SMN correctors. **SRK-015 is an investigational therapyunder development.&#160;&#160;SMN Upregulator Therapies* + Muscle-Directed Therapy (SRK-015) Could Potentially Enhance Outcomes for
              Patients&#160;&#160;SRK-015**&#160;&#160;SMN Upregulator TherapiesAddress SMN deficiency to prevent further motor neuron deterioration &#160;&#160;Muscle-Directed TherapiesAct directly on muscle with aim to improve motor function &#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide5.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Fully human monoclonal antibody (mAb)Half-life of ~23-33 daysAvoids related growth factors (e.g. GDF11,
              BMP9, Activin A)Rare Pediatric Disease Designation for SMA granted by FDA Orphan Drug Designation for SMA granted by the FDAOrphan Medicinal Product Designation for SMA granted by the European Commission&#160;&#160;SRK-015: Highly Selective Inhibitor
              of the Activation of Pro and Latent Myostatin&#160;&#160;5&#160;&#160;Highlights of strong patent portfolio protecting SRK-015:US Patent 10,751,413 (expiry in 2037): Covers composition of matter and methods of use for SRK-015US Patent 9,758,576 (expiry in 2034):
              Covers mAbs that inhibit the activation of myostatin precursorUS 10,287,345 (expiry in 2037): Treatment methods for various myostatin-related conditions &#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide6.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;6&#160;&#160;Bringing a Revolutionary Approach to Highly Sought-After Growth Factors Implicated in Devastating
              Diseases&#160;&#160;&#160;&#160;Scholar Rock&#8217;s Target&#160;&#160;Growth Factor Precursor (Latent Form)&#160;&#160;Scholar Rock&#8217;s R&amp;D PlatformTransform Medical Practice&#160;&#160;Pursue important targets with well-validated biology but are difficult to drugApply revolutionary approach to
              tough targetsLeverage deep insights into structure and function Engineer antibodies for exquisite selectivity&#160;&#160;First demonstration of the therapeutic potential of inhibiting the latent forms of growth factors&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide7.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;7&#160;&#160;Mean improvements from baseline in HFMSE/RHS observed in each of the 3 cohorts67% of total patients
              achieved &#8805;1-point improvement in Hammersmith scoresSubstantial proportion of patients in each cohort attained &#8805;3-point improvement in HFMSE/RHSHigh bar and uncommon to observe in any given patient35% of total patients achieved &#8805;3-point
              improvement in Hammersmith scoresDose response demonstrated in Cohort 3 (randomized, double-blind, parallel arm design)Greater improvements in HFMSE scores for high-dose arm across evaluated timepointsSupportive PK/PD results; high dose led
              to higher drug exposure and target engagement&#160;&#160;TOPAZ Interim Analysis Results Demonstrate Proof-of-ConceptMultiple lines of evidence supporting the potential clinical effect of SRK-015 &#160;&#160;&#160;&#160;Ambulatory Patients(Revised Hammersmith
              Scale)&#160;&#160;&#160;&#160;&#160;&#160;Non-Ambulatory Patients(Hammersmith Functional Motor Scale Expanded)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cohort 1&#160;&#160;&#160;&#160;&#160;&#160;Cohort 2*&#160;&#160;Cohort 3*&#160;&#160;&#160;&#160;&#160;&#160;20 mg/kg pooled (n=23)&#160;&#160;20 mg/kgmonotherapy (n=11)&#160;&#160;20 mg/kg +nusinersen (n=12)&#160;&#160;20 mg/kg +nusinersen (n=14)&#160;&#160;2
              mg/kg +nusinersen(n=9)&#160;&#160;20 mg/kg +nusinersen(n=9)&#160;&#160;Mean change from baseline (95% CI)&#160;&#160;0.5 (-1.1, 2.2)&#160;&#160;0.7 (-2.5, 4.0)&#160;&#160;0.3 (-1.4, 2.0)&#160;&#160;1.4 (0.1, 2.7)&#160;&#160;2.4 (-0.9, 5.8)&#160;&#160;5.6 (2.5, 8.7)&#160;&#160;# (%) patients achieving &#8805;1-pt increase&#160;&#160;12/23
              (52%)&#160;&#160;7/11 (64%)&#160;&#160;5/12 (42%)&#160;&#160;10/14 (71%)&#160;&#160;6/9 (67%)&#160;&#160;9/9 (100%)&#160;&#160;# (%) patients achieving &#8805;3-pt increase&#160;&#160;6/23 (26%)&#160;&#160;4/11 (36%)&#160;&#160;2/12 (17%)&#160;&#160;3/14 (21%)&#160;&#160;4/9 (44%)&#160;&#160;6/9 (67%)&#160;&#160;*3 patients (1 in Cohort 2 and 2 in Cohort 3) each missed 3
              doses of SRK-015 and the 6-month interim analysis timepoint due to COVID-19-related site access restrictions; the six-month timepoint from these patients was not included in the interim analysis. Data on file. Scholar Rock, Inc. Cambridge,
              MA&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide8.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Phase 2 Trial Design and Baseline Characteristics&#160;&#160;Yung Chyung, M.D.Chief Medical Officer&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide9.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;9&#160;&#160;Next Era of SMA Treatment: Muscle-Directed Therapy&#160;&#160;&#160;&#160;Overall Prevalence of 30,000-35,000 in U.S.
              and Europe&#160;&#160;Type 114%&#160;&#160;Type 251%&#160;&#160;Type 335%&#160;&#160;HFMSE = Hammersmith Functional Motor Scale Expanded &#160;&#160;Relative Prevalence Among Patients Living With SMA&#160;&#160;Unmet need would be served by a therapy that:Improves motor functionSafety profile that
              enables chronic dosing, including in the pediatric populationLow drug administration burdenApplicable across SMA types&#160;&#160;TOPAZ trial focuses on Type 2 and Type 3 SMA&#160;&#160;Type 1: Infant-onsetUsually fatal without treatment Type 2 and
              non-ambulatory Type 3: Later-onset but still early childhoodSevere deficits in motor functionSMN upregulators appear to primarily stabilize disease courseAmbulatory Type 3: Typically childhood-onsetWide range of motor function deficits;
              limited mobility and substantial morbiditySMN upregulators appear to primarily stabilize disease course&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide10.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SRK-015 Phase 2 Trial Design&#160;&#160;Design&#160;&#160;Patients&#160;&#160;Primary Objectives&#160;&#160;HFMSE=Hammersmith Functional Motor
              Scale Expanded; RHS=Revised Hammersmith ScaleData on file. Scholar Rock, Inc. Cambridge, MA&#160;&#160;Evaluate potential of SRK-015 in improving motor function&#160;&#160;10&#160;&#160;&#160;&#160;Ambulatory Patients(Revised Hammersmith Scale)&#160;&#160;Non-Ambulatory Patients(Hammersmith
              Functional Motor Scale Expanded)&#160;&#160;&#160;&#160;Cohort 1&#160;&#160;Cohort 2&#160;&#160;Cohort 3&#160;&#160;N= 23; ages 5-21Open-label, single-arm20 mg/kg SRK-015 IV Q4W12-month treatment period &#160;&#160;N= 15; ages 5-21 Open-label, single-arm20 mg/kg SRK-015 IV Q4W12-month treatment
              period&#160;&#160;N= 20; ages &#8805;2Double-blind, randomized (1:1) to 2 mg/kg or 20 mg/kg SRK-015 IV Q4W12-month treatment period&#160;&#160;Ambulatory Type 3 SMATwo subgroups: Receiving background nusinersen SRK-015 monotherapy&#160;&#160;Type 2 or non-ambulatory Type 3
              SMAReceiving background nusinersen&#160;&#160;Type 2 SMA Receiving background nusinersen (initiated before age 5)&#160;&#160;SafetyMean change from baseline in RHS&#160;&#160;SafetyMean change from baseline in HFMSE&#160;&#160;SafetyMean change from baseline in HFMSE&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide11.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Baseline Characteristics&#160;&#160;11&#160;&#160;&#160;&#160;Ambulatory Patients&#160;&#160;&#160;&#160;&#160;&#160;Non-Ambulatory Patients&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cohort
              1&#160;&#160;&#160;&#160;&#160;&#160;Cohort 2&#160;&#160;Cohort 3&#160;&#160;&#160;&#160;&#160;&#160;20 mg/kgpooled &#160;&#160;20 mg/kgmonotherapy&#160;&#160;20 mg/kg +nusinersen&#160;&#160;20 mg/kg +nusinersen&#160;&#160;2 mg/kg +nusinersen&#160;&#160;20 mg/kg +nusinersen&#160;&#160;N&#160;&#160;23&#160;&#160;11&#160;&#160;12&#160;&#160;15&#160;&#160;10&#160;&#160;10&#160;&#160;Mean age (min, max)&#160;&#160;12.6 (7, 21)&#160;&#160;12.1 (7, 19)&#160;&#160;13.1 (7,
              21)&#160;&#160;11.7 (8, 19)&#160;&#160;4.1 (2, 6)&#160;&#160;3.8 (2, 6)&#160;&#160;Female (%)&#160;&#160;65%&#160;&#160;73%&#160;&#160;58%&#160;&#160;53%&#160;&#160;30%&#160;&#160;50%&#160;&#160;SMN2 Gene Copy* (#, %)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2&#160;&#160;1 (4%)&#160;&#160;1 (9%)&#160;&#160;0 (0%)&#160;&#160;&#160;&#160;1 (10%)&#160;&#160;1 (10%)&#160;&#160;3&#160;&#160;13 (57%)&#160;&#160;4 (36%)&#160;&#160;9 (75%)&#160;&#160;11 (73%)&#160;&#160;8 (80%)&#160;&#160;8 (80%)&#160;&#160;4&#160;&#160;5 (22%)&#160;&#160;4
              (36%)&#160;&#160;1 (8%)&#160;&#160;2 (13%)&#160;&#160;1 (10%)&#160;&#160;0 (0%)&#160;&#160;Mean # of nusinersen maintenance doses&#160;&#160;N/A&#160;&#160;N/A&#160;&#160;5.6&#160;&#160;5.1&#160;&#160;5.5&#160;&#160;5.4&#160;&#160;Discontinuation(s)&#160;&#160;1**&#160;&#160;0&#160;&#160;1**&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;Mean RHS score (min, max)&#160;&#160;49.6 (26, 63)&#160;&#160;47.6 (26, 63)&#160;&#160;51.3 (43, 62)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mean HFMSE
              score (min, max)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;22.7 (13, 39)&#160;&#160;26.1 (12, 44)&#160;&#160;23.5 (14, 42)&#160;&#160;*data not available for all patients**patient who discontinued study for reasons unrelated to study drug&#160;&#160;HFMSE=Hammersmith Functional Motor Scale Expanded; RHS=Revised
              Hammersmith ScaleData on file. Scholar Rock, Inc. Cambridge, MA&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide12.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;12&#160;&#160;Key Strengths of TOPAZ Trial Design and Conduct&#160;&#160;Large and diverse group of study sites for a rare
              disease trialPatients enrolled across 16 study sites in the U.S. and EuropePatient enrollment was not skewed to any one site for any cohort or across the studyPrimary efficacy endpoints are well-validated outcome measuresHammersmith
              Functional Motor Scale Expanded (HFMSE) was specifically designed for SMA and served as primary efficacy endpoint in Phase 3 CHERISH trial of nusinersenRevised Hammersmith Scale (RHS) is very similar to the HFMSE, with some modification to
              reduce ceiling effects in assessing patients who are ambulatory Efficacy assessments are being conducted in a rigorous fashion:Standardized conduct of Hammersmith scale assessments; extensive training of all trial sitesAssessors of the
              Hammersmith scale measures are blinded to baseline and prior visit scoresEmbedded randomized, double-blind portion of trial (Cohort 3) to evaluate dose response between high and low dose arms of SRK-015&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide13.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;13&#160;&#160;Six-Month Interim Analysis Results&#160;&#160;Yung Chyung, M.D.Chief Medical Officer&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide14.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;14&#160;&#160;Mean improvements from baseline in HFMSE/RHS observed in each of the 3 cohorts67% of total patients
              achieved &#8805;1-point improvement in Hammersmith scoresSubstantial proportion of patients in each cohort attained &#8805;3-point improvement in HFMSE/RHSHigh bar and uncommon to observe in any given patient35% of total patients achieved &#8805;3-point
              improvement in Hammersmith scoresDose response demonstrated in Cohort 3 (randomized, double-blind, parallel arm design)Greater improvements in HFMSE scores for high-dose arm across evaluated timepointsSupportive PK/PD results; high dose led
              to higher drug exposure and target engagement&#160;&#160;TOPAZ Interim Analysis Results Demonstrate Proof-of-ConceptMultiple lines of evidence supporting the potential clinical effect of SRK-015 &#160;&#160;&#160;&#160;Ambulatory Patients(Revised Hammersmith
              Scale)&#160;&#160;&#160;&#160;&#160;&#160;Non-Ambulatory Patients(Hammersmith Functional Motor Scale Expanded)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cohort 1&#160;&#160;&#160;&#160;&#160;&#160;Cohort 2*&#160;&#160;Cohort 3*&#160;&#160;&#160;&#160;&#160;&#160;20 mg/kg pooled (n=23)&#160;&#160;20 mg/kgmonotherapy (n=11)&#160;&#160;20 mg/kg +nusinersen (n=12)&#160;&#160;20 mg/kg +nusinersen (n=14)&#160;&#160;2
              mg/kg +nusinersen(n=9)&#160;&#160;20 mg/kg +nusinersen(n=9)&#160;&#160;Mean change from baseline (95% CI)&#160;&#160;0.5 (-1.1, 2.2)&#160;&#160;0.7 (-2.5, 4.0)&#160;&#160;0.3 (-1.4, 2.0)&#160;&#160;1.4 (0.1, 2.7)&#160;&#160;2.4 (-0.9, 5.8)&#160;&#160;5.6 (2.5, 8.7)&#160;&#160;# (%) patients achieving &#8805;1-pt increase&#160;&#160;12/23
              (52%)&#160;&#160;7/11 (64%)&#160;&#160;5/12 (42%)&#160;&#160;10/14 (71%)&#160;&#160;6/9 (67%)&#160;&#160;9/9 (100%)&#160;&#160;# (%) patients achieving &#8805;3-pt increase&#160;&#160;6/23 (26%)&#160;&#160;4/11 (36%)&#160;&#160;2/12 (17%)&#160;&#160;3/14 (21%)&#160;&#160;4/9 (44%)&#160;&#160;6/9 (67%)&#160;&#160;*3 patients (1 in Cohort 2 and 2 in Cohort 3) each missed 3
              doses of SRK-015 and the 6-month interim analysis timepoint due to COVID-19-related site access restrictions; the six-month timepoint from these patients was not included in the interim analysis. Data on file. Scholar Rock, Inc. Cambridge,
              MA&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide15.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;Cohort 1: Improvement in RHS Observed with Both SRK-015 Monotherapy and as Add-on to Background
              Nusinersen&#160;&#160;15&#160;&#160;Individual RHS responses&#160;&#160;Ambulatory Type 3 SMA&#160;&#160;SRK-015 (20 mg/kg)pooled (n=23)&#160;&#160;SRK-015 (20 mg/kg)monotherapy (n=11)&#160;&#160;SRK-015 (20 mg/kg) +nusinersen (n=12)&#160;&#160;Mean change from baseline in RHS (95% CI)&#160;&#160;0.5 (-1.1, 2.2)&#160;&#160;0.7
              (-2.5, 4.0)&#160;&#160;0.3 (-1.4, 2.0)&#160;&#160;# (%) patients achieving &#8805;1-pt increase in RHS&#160;&#160;12/23 (52%)&#160;&#160;7/11 (64%)&#160;&#160;5/12 (42%)&#160;&#160;# (%) patients achieving &#8805;3-pt increase in RHS&#160;&#160;6/23 (26%)&#160;&#160;4/11 (36%)&#160;&#160;2/12 (17%)&#160;&#160;# (%) patients achieving &#8805;5-pt increase in
              RHS&#160;&#160;2/23 (9%)&#160;&#160;1/11 (9%)&#160;&#160;1/12 (8%)&#160;&#160;Mean (&#177;SEM) change from baseline in RHS scores &#160;&#160;N=&#160;&#160;Data on file. Scholar Rock, Inc. Cambridge, MA&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide16.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Cohort 2: Meaningful and Consistent Improvements in HFMSE Observed in Type 2 and Non-Ambulatory Type
              3 SMA&#160;&#160;Individual HFMSE responses&#160;&#160;Type 2 and Non-Ambulatory Type 3 SMA&#160;&#160;SRK-015 (20 mg/kg) + nusinersen (n=14)&#160;&#160;Mean change from baseline in HFMSE (95% CI)&#160;&#160;1.4 (0.1, 2.7)&#160;&#160;# (%) patients achieving &#8805;1-pt increase in HFMSE&#160;&#160;10/14 (71%)&#160;&#160;# (%)
              patients achieving &#8805;3-pt increase in HFMSE&#160;&#160;3/14 (21%)&#160;&#160;# (%) patients achieving &#8805;5-pt increase in HFMSE&#160;&#160;2/14 (14%)&#160;&#160;16&#160;&#160;Mean (&#177;SEM) change from baseline in HFMSE scores &#160;&#160;&#160;&#160;N=&#160;&#160;Data on file. Scholar Rock, Inc. Cambridge, MA&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide17.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Cohort 3: SRK-015 High Dose Showed Substantially Greater Improvements in HFMSE scores Than Low Dose
              &#160;&#160;17&#160;&#160;Individual HFMSE responses&#160;&#160;Type 2 SMA&#160;&#160;SRK-015 low dose (2 mg/kg) +nusinersen (n=9)&#160;&#160;SRK-015 high dose (20 mg/kg) +nusinersen (n=9)&#160;&#160;Mean change from baseline in HFMSE (95% CI)&#160;&#160;2.4 (-0.9, 5.8)&#160;&#160;5.6 (2.5, 8.7)&#160;&#160;# (%) patients achieving
              &#8805;1-pt increase in HFMSE&#160;&#160;6/9 (67%)&#160;&#160;9/9 (100%)&#160;&#160;# (%) patients achieving &#8805;3-pt increase in HFMSE&#160;&#160;4/9 (44%)&#160;&#160;6/9 (67%)&#160;&#160;# (%) patients achieving &#8805;5-pt increase in HFMSE&#160;&#160;3/9 (33%)&#160;&#160;5/9 (56%)&#160;&#160;Cohort 3 has a randomized, double-blind, parallel
              arm design embedded within TOPAZ&#160;&#160; &#160;&#160;Mean (&#177;SEM) change from baseline in HFMSE scores &#160;&#160;N=&#160;&#160;Data on file. Scholar Rock, Inc. Cambridge, MA&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide18.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Cohort 3: Time Course Data Supportive of Dose Response&#160;&#160;18&#160;&#160;Mean (&#177;SEM) change from baseline in HFMSE
              scores &#160;&#160;Greater improvements in HFMSE scores observed with high dose (20 mg/kg) across all timepoints&#160;&#160;High-dose arm outperformed low-dose arm numerically across the timepointsPlateau in improvement appears to not yet have been reached at
              the 6-month interim analysis timepoint12-month and extension data enable evaluating the potential for durability of effect and for further motor function gains&#160;&#160;N=&#160;&#160;Data on file. Scholar Rock, Inc. Cambridge, MA&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide19.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Well-behaved PK profile consistent with that commonly observed with monoclonal antibodiesDrug exposure
              was dose proportional&#160;&#160;Pharmacokinetic and Pharmacodynamic Data are Supportive of Clinically Observed Dose Response &#160;&#160;Pharmacokinetics* (PK)&#160;&#160;Pharmacodynamics (PD)&#160;&#160;Target engagement by SRK-015 was confirmedLow dose (2 mg/kg) yielded lower
              level of target engagement and did not achieve full target saturation&#160;&#160;High dose (20 mg/kg) yielded higher levels of drug exposure and target engagement than low dose (2 mg/kg)&#160;&#160;19&#160;&#160;*Starting at day 28, measures are pre-dose trough
              levels&#160;&#160;Data on file. Scholar Rock, Inc. Cambridge, MA&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide20.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;No Safety Signals Identified from Interim Analysis&#160;&#160;20&#160;&#160;Treatment-emergent adverse events
              (TEAEs)&#160;&#160;SRK-015 2 mg/kg dose (n=10)&#160;&#160;SRK-015 20 mg/kg dose (n=48)&#160;&#160;Total(n=58)&#160;&#160;Any TEAE&#160;&#160;9 (90%)&#160;&#160;40 (83.3%)&#160;&#160;49 (84.5%)&#160;&#160;Any Serious TEAE&#160;&#160;0 (0.0%)&#160;&#160;1 (2.1%)&#160;&#160;1 (1.7%)&#160;&#160;Any TEAE leading to study drug discontinuation&#160;&#160;0 (0.0%)&#160;&#160;1 (2.1%)&#160;&#160;1
              (1.7%)&#160;&#160;Any Grade 3 (severe) or higher TEAE&#160;&#160;0 (0.0%)&#160;&#160;0 (0.0%)&#160;&#160;0 (0.0%)&#160;&#160;Treatment-emergent adverse events (TEAEs) are defined as AEs that start after the first dose of study drug or start prior to the administration of study drug and
              worsen in severity/grade or relationship to investigational medication after the administration of study drug.Data on file. Scholar Rock, Inc. Cambridge, MA&#160;&#160;Five most frequently reported TEAEs: Headache, upper respiratory tract infection,
              pyrexia, nasopharyngitis, and cough.1 serious TEAE (Cohort 1): Assessed by trial investigator as unrelated to SRK-015. Grade 2 viral upper respiratory infection (prior history) and was hospitalized. Event resolved without sequelae.1 study
              drug discontinuation (Cohort 1): Assessed by trial investigator as unrelated to SRK-015. Grade 2 leg muscle fatigue (developed prior to enrollment). Withdrew consent after ~2 months on trial. &#160;&#160;Incidence and severity of AEs are consistent
              with underlying patient population and background therapy&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide21.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;21&#160;&#160;TOPAZ Interim Analysis Results Demonstrate Proof-of-Concept&#160;&#160;Mean improvements in Hammersmith
              scores observed across all 3 cohortsMost patients experienced an improvement (&#8805;1-pt increase in Hammersmith scores)Cohort 1: 52% (pooled)Cohort 2: 71% Cohort 3: 100% high dose, 67% low dosePotential for durability and further
              improvementsEffects observed through 6 months of treatmentPlateau in improvement has not yet been observed in Cohorts 2 or 312-month and extension data enable evaluation for potential durability of effect and further improvements&#160;&#160;Dose
              response demonstrated in randomized, double-blind, parallel arm Cohort 3High-dose arm showed greater improvements in HFMSE scoresSupportive PK/PD resultsCohort 2 observed improvements from baselineIn population for which SMN upregulator
              therapy alone offers motor function stabilization rather than improvementSubstantial % of patients in each cohort attained &#8805;3-pt increase in Hammersmith scoreHigh bar and uncommon to observe in any given patient&#160;&#160;2. SRK-015&#8217;s broad and
              meaningful therapeutic potential in SMA&#160;&#160;1. Multiple lines of evidence supporting the potential clinical effect of SRK-015 &#160;&#160;Data on file. Scholar Rock, Inc. Cambridge, MA&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide22.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;22&#160;&#160;Summary and Next StepsTony KingsleyPresident &amp; CEO&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide23.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;23&#160;&#160;Top-line data for 12-month treatment period expected 2Q21Longer-term evaluation of efficacy for
              potential durability of clinical effect and continued motor function gainsLonger-term safety, PK, PD, and anti-drug antibody39 of 39 patients who have completed 12-month study have opted into the extension period (as of October 23,
              2020)Registrational trial preparations ongoingLook forward to meeting with regulatory authorities to discuss regulatory path&#160;&#160;Beyond the TOPAZ Interim Analysis&#160;&#160;&#160;&#160;Interim results highlight SRK-015&#8217;s potential as an important treatment for
              patients with SMA&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide24.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;24&#160;&#160;Unlocking the Potential of the Scholar Rock R&amp;D Engine&#160;&#160;&#160;&#160;&#160;&#160;Scholar Rock seeks to unlock the
              therapeutic potential of modulating growth factor biology&#160;&#160;Targeting the latent forms of growth factors&#160;&#160;Opportunities to Further Investigate Therapeutic Potential&#160;&#160;Broader exploration of SMA types, age range, and background SMN
              therapiesPotential for motor function improvement in other neuromuscular disordersExploration of additional indications related to broader myostatin and fast-twitch fiber biologyAntibodies against the latent forms of additional well-validated
              targets in oncology (e.g. SRK-181 program) and fibrosisDiscovery platform to generate mAbs against other latent growth factors&#160;&#160;Emerging Insights&#160;&#160;Demonstration of proof-of-concept for SRK-015 in SMA&#160;&#160;Validation of therapeutic potential for
              blocking the activation of latent myostatin with SRK-015&#160;&#160;Validation of therapeutic potential in targeting latent forms of growth factors&#160;&#160;&#160;&#160;Emerging Insights&#160;&#160;Opportunities Beyond TOPAZ&#160;&#160;&#160;&#160;TGF&#946; Superfamily: More than 30 Related Growth
              Factors that Mediate Diverse Biological Processes&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide25.jpg"></div>
        </div>
        <div id="slideText" style="text-align: center;">
          <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;DRAGON Part B Initiation&#160;&#160;&#160;&#160;Gilead Fibrosis-focused TGF&#946; Collaboration&#160;&#160;&#160;&#160;&#160;&#160;DRAGON Clinical Response
              and Safety Data Across Multiple Tumor TypesPart A2 Combo Efficacy and Safety DataPart B &#8211; MelanomaPart B &#8211; NSCLCPart B &#8211; Urothelial CarcinomaPart B &#8211; Other Solid Tumor Types&#160;&#160;SRK-015SMA&#160;&#160;SRK-181 Immuno-Oncology and Oncology&#160;&#160;Preclinical /
              Platform&#160;&#160;&#160;&#160;TOPAZ Topline12M Data(3 Cohorts)&#160;&#160;Potential SRK-015 Phase 3 in SMA&#160;&#160;TOPAZ Interim Analysis(3 Cohorts)&#160;&#160;Differentiated Pipeline with a Series of Anticipated Milestones&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TOPAZ 2 Year Extension&#160;&#160;Continue to Discover and Advance
              Preclinical Programs&#160;&#160;Update on Dose Escalation&#160;&#160;Multiple Opportunities for Additional Indications Beyond SMA&#160;&#160;&#160;&#160;Multiple Additional Opportunities: 1) SRK-181 in Oncology; 2) Latent TGF&#946;1 Immune Cell in IO; 3) Latent TGF&#946;1 Immune Cell in
              Oncology&#160;&#160;SRK-015Other Indications&#160;&#160;Gilead Fibrosis collaboration&#160;&#160;&#160;&#160;&#160;&#160;2022 and Beyond&#160;&#160;2021&#160;&#160;Q4 2020&#160;&#160;Q3&#160;&#160;Q4&#160;&#160;Q1&#160;&#160;Q2&#160;&#160;Latent TGF&#946;1 Immune Cell Immuno-Oncology and Oncology&#160;&#160;25&#160;&#160;&#160;</font></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div id="slide" style="text-align: center;">
        <div id="frame" style="position: relative; left: 0px; top: 0px;">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/0cd29505be1d9292402be8df01d04a5f-a52314353ex99_2slide26.jpg"></div>
        </div>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;">&#160;</div>
      <div id="spaceAfterSlideText" style="text-align: center;"> <br>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;"> <br>
      </div>
      <div id="spaceAfterSlideText" style="text-align: center;"> <br>
      </div>
    </div>
    <br>
  </div>
</body>
</html>


  </div>

  </div>

          <script type="text/javascript">var s_CCSWebHostingAccount = "trcgscholarrock";</script>
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/7721\/html","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb56236\/themes\/site\/nir_pid2662"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"user":{"uid":0,"permissionsHash":"4506f7b957b4baf2488ee006e9b884f3b49293f46cfb6e03ffbb15fedba12da4"}}</script>
<script src="../../sites/g/files/knoqqb56236/files/js/js_D31miEwayYNfIODJWy2ump8i_gwklTzvOKq4eFgXiKw4996.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl"></script>
<script src="../../../assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" crossorigin="anonymous" async integrity="sha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf"></script>

  </body>
</html>
